Difficulty swallowing affects about one-third of patients with multiple sclerosis.
Dysphagia, or difficulty swallowing, after a multiple sclerosis (MS) diagnosis is a common symptom and is estimated to affect one-third of the patients with MS. A recent review described the strategies used to identify and assess swallowing dysfunctions in MS patients with dysphagia and said that new tools are needed.
Swallowing may be impaired in MS as a result of lesions in corticobulbar tracts, paresis of cranial nerves, disorders of cerebellum and brainstem, and cognitive dysfunctions. Dysphagia may cause serious complications such as aspiration pneumonia, malnutrition, dehydration, and airway obstruction. Patients may have difficulty swallowing and not realize it, the authors said, making screening essential.
Assessment for dysphagia is essential as it may reduce the risk of complications such as pneumonia, improve health outcomes, and lower healthcare costs.
The authors categorized screening strategies into 2 types:
While a variety of non-instrumental screening tools are available, only the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS) and the Mann Assessment of Swallowing Ability (MASA) are validated specifically for MS-related dysphagia, the authors said.
However, psychometric evidence about the DYMUS questionnaire and the MASA test have been incompletely evaluated.
The Eating Assessment Tool (EAT-10) is a commonly used self-administered and symptom-specific patient-reported outcome questionnaire for assessing the patient’s perception of dysphagia in various clinical diagnoses, including MS. It is a is a validated, easy to use, easily read and understood outcome tool; the authors suggested that it be specifically validated in patients with MS.
Another test, the 3-ounce water swallow test, is a widely used sensitive test, but it has not been validated in the MS population, the researchers noted. Other tests include the Dysphagia Screening Questionnaire for MS (DSQMS) and the Northwestern Dysphagia Patient Check Sheet (NDPCS),
Instrumental screening assesses the body structure and function of swallowing; 2 such tests are the Videofluoroscopic Swallowing Examination Strategy (VFSS), or modified barium swallowing study, and the Fiberoptic Endoscopic Examination of Swallowing (FEES). VFSS is considered the gold standard and the FEES ss the second most commonly used test.
The VFSS is an X-ray visualization to determine the nature and extent of the swallowing dysfunctions; it identifies the swallowing dysfunctions by providing a real-time visualization of bolus flow, allows structural kinematic analysis, and detects aspiration. However, the authors said studies on VFSS in patients with MS are scarce.
Until new tools are developed, validation and metric evaluation of current screening and assessment tools are required, the authors said.
Reference
Nakhostin Ansari N, Tarameshlu M, Ghelichi L. Dysphagia in multiple sclerosis patients: Diagnostic and evaluation strategies [published online March 26, 2020]. Degener Neurol Neuromuscul Dis. doi: 10.2147/DNND.S198659
Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS
November 21st 2023Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Read More
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
October 23rd 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More